Diagnostics News and Research RSS Feed - Diagnostics News and Research

Cell-signaling protein holds key to understanding autoantibody formation in lupus patients

Cell-signaling protein holds key to understanding autoantibody formation in lupus patients

A signaling molecule called interferon gamma could hold the key to understanding how harmful autoantibodies form in lupus patients. The finding could lead to new treatments for the chronic autoimmune disease, said researchers at Penn State College of Medicine. [More]
PATH and SD/Alere announce commercial availability of two diagnostic tools for NTDs

PATH and SD/Alere announce commercial availability of two diagnostic tools for NTDs

PATH and Standard Diagnostics/Alere announced today the commercial availability of two rapid diagnostic tools for onchocerciasis and lymphatic filariasis. Designed for use in disease surveillance, the antibody-based tests are part of a suite of diagnostic innovations intended to support the elimination of neglected tropical diseases (NTDs), a group of illnesses that affect more than a billion people worldwide. [More]
New data from studies evaluating diagnostic tools, therapies for infectious diseases released at ECCMID 2016

New data from studies evaluating diagnostic tools, therapies for infectious diseases released at ECCMID 2016

New data from ten late-breaking abstracts is released at ECCMID 2016 – the annual meeting of the European Society of Clinical Microbiology and Infectious Disease. [More]
Advanced assay offers better sensitivity for detecting a prion disease affecting elk

Advanced assay offers better sensitivity for detecting a prion disease affecting elk

Transmissible spongiform encephalopathies (TSEs), or prion diseases, are a family of rare progressive, neurodegenerative illnesses that affect both humans and animals. TSE surveillance is important for public health and food safety because TSEs have the potential of crossing from animals to humans, as seen with the spread of mad cow disease, or bovine spongiform encephalopathy (BSE). A study in The Journal of Molecular Diagnostics describes an advanced assay that offers better sensitivity than currently available tests for detecting a prion disease affecting elk. [More]
Newcastle scientists develop new type of genetic blood test to diagnose liver scarring

Newcastle scientists develop new type of genetic blood test to diagnose liver scarring

Newcastle scientists and medics have developed a new type of genetic blood test that diagnoses scarring in the liver - even before someone may feel ill. [More]
Advances in NMR metabolomics: an interview with Professor Tone F. Bathen

Advances in NMR metabolomics: an interview with Professor Tone F. Bathen

The main objective of our research is to improve and individualize cancer diagnostics and cancer treatment. We try to achieve this through the integrated use of MR technology and the development of data-driven tools to analyze tumors on both a functional and molecular level. [More]
The Weizmann Institute of Science purchases novel Aeon™ 1GHz NMR system from Bruker

The Weizmann Institute of Science purchases novel Aeon™ 1GHz NMR system from Bruker

The Weizmann Institute of Science in Rehovot, Israel today announced major scientific instrument purchases from Bruker (NASDAQ: BRKR), including a novel Aeon™ 1GHz nuclear magnetic resonance (NMR) system for expanding frontiers in structural biology and intrinsically disordered protein (IDPs) research. Furthermore, the Weizmann Institute is adding an Aeon 600 MHz NMR, a 263 GHz dynamic nuclear polarization (DNP)-NMR system, and a Biospec® 15 Tesla system for preclinical ultra-high field magnetic resonance imaging (MRI). Various NMR and electron paramagnetic resonance (EPR) instrument upgrades round out this major acquisition, instantly propelling the Weizmann Institute to the frontiers of modern magnetic resonance research infrastructure. [More]
Clinical study shows association between Corus CAD blood test scores and cardiovascular event rates

Clinical study shows association between Corus CAD blood test scores and cardiovascular event rates

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today results from a genomic substudy of the NHLBI-funded Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial in nondiabetic patients receiving the Corus CAD blood test. [More]
Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph's Hospital and Medical Center. [More]
SymCel joins global initiative to combat antibiotic resistance

SymCel joins global initiative to combat antibiotic resistance

Following the global and joint initiative by the pharmaceutical, biotechnology and diagnostics industries this year to combat antibiotic resistance, demand for innovative solutions is especially high. The event took place in January at the World Economic Forum in Davos. [More]
Investigational stem cell therapy improves outcomes in patients with severe heart failure

Investigational stem cell therapy improves outcomes in patients with severe heart failure

An investigational stem cell therapy derived from patients' own blood marrow significantly improved outcomes in patients with severe heart failure, according to a study from the Cedars-Sinai Heart Institute. [More]
Increased consumption of antibiotics in childhood may lead to adolescent prediabetes

Increased consumption of antibiotics in childhood may lead to adolescent prediabetes

Young children who take antibiotics may disrupt their gut's microbial ecosystem and be more likely to develop prediabetes in adolescence, new research from Greece reports. The study results will be presented in a poster Sunday, April 3, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston. [More]
Startupbootcamp introduces Digital Health accelerator in Berlin

Startupbootcamp introduces Digital Health accelerator in Berlin

Startupbootcamp, a global accelerator group with industry-focused programs, launches its first Digital Health accelerator in Europe today. [More]
Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

PharmaMar today announced positive top-line results of its Phase III clinical trial -ADMYRE- with Aplidin (plitidepsin) in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM). [More]
MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

A recent study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine showed that a microRNA called miR-181a dampens signals from the cancer-driving NFκB protein pathway in the most aggressive large B-cell lymphomas (DLBCL). By reducing NFκB signaling, miR-181a controls tumor cell proliferation and survival and could be the target of novel therapies. The study was published in the journal Blood. [More]
GHIT Fund invests in two innovative malaria eradication tools

GHIT Fund invests in two innovative malaria eradication tools

The Global Health Innovative Technology Fund (GHIT Fund) announced today that it’s investing US$1,383,785 in a pair of innovative malaria eradication tools—a vaccine that could block transmission of two species of the deadly disease and a rapid field test that can reveal a malaria infection in minutes. [More]
Experimental urine test identifies 92% of men with elevated PSA levels

Experimental urine test identifies 92% of men with elevated PSA levels

An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA (prostate-specific antigen) levels who had high-grade cancers, according to a study published today in JAMA Oncology online. [More]
Myriad myRisk Hereditary Cancer test identifies 70% more deleterious mutations than BRCA1/2 testing alone

Myriad myRisk Hereditary Cancer test identifies 70% more deleterious mutations than BRCA1/2 testing alone

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, working in collaboration with researchers from the Harvard Medical School, today announced that the Journal of Clinical Oncology has published a paper showing the frequency of germline mutations in 25 cancer susceptibility genes among patients with breast cancer. [More]
New device can deliver diagnosis to patient in 30 minutes

New device can deliver diagnosis to patient in 30 minutes

When a person contracts a disease, it takes time to diagnose the symptoms. Cell culturing, immunoassay and a nucleic-acid based diagnostic cycle all take several days, if not a week to determine the results. Not only do sick patients suffer during this time period, the wait can also lead to unnecessary disease spreading and perhaps avoidable antibiotic use. [More]
Cairn launches non-invasive Gastric Emptying Breath Test for measuring rate of gastroparesis in adults

Cairn launches non-invasive Gastric Emptying Breath Test for measuring rate of gastroparesis in adults

Cairn Diagnostics, formerly known as Advanced Breath Diagnostics (ABDiagnostics), has launched the 13C-Spirulina Gastric Emptying Breath Test (GEBT). [More]
Advertisement
Advertisement